By Elaine Rigoli
Tampa, Fla., May 25 - Lux Biosciences, Inc. announced the close of a $36 million series A financing round, which includes equal participation of funds managed by HBM Partners AG, Novo A/S and SV Life Sciences.
As part of the transaction, Axel Bolte, investment adviser at HBM Partners, Thomas Dyrberg, partner at Novo A/S, and Lutz Giebel, general partner at SV Life Sciences, will join the Lux Biosciences board.
The company also announced that it had signed a worldwide license agreement with Isotechnika, Inc. granting Lux exclusive worldwide rights to develop and commercialize Isotechnika's flagship phase 3 product candidate, ISA247, a next-generation calcineurin inhibitor, for the treatment and prophylaxis of all ophthalmic diseases.
Lux Biosciences, located in Jersey City, N.J., is a privately held biotechnology company specializing in the field of ophthalmic diseases.
| Issuer: | Lux Biosciences, Inc.
|
| Issue: | Series A financing
|
| Amount: | $36 million
|
| Investors: | HBM Partners AG, Novo A/S and SV Life Sciences
|
| Announcement date: | May 25
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
